Fesoterodine
Brand names: Toviaz
Fesoterodine is an antimuscarinic prodrug used to treat the symptoms of overactive bladder, including urgency, frequency and urge incontinence.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is rapidly converted to its active metabolite, which antagonises muscarinic receptors on the detrusor muscle to reduce involuntary bladder contractions.
Prescribing in practice
- It is contraindicated in urinary retention, gastric retention and uncontrolled narrow-angle glaucoma owing to its antimuscarinic actions.
- Dry mouth and constipation are the most frequent adverse effects and can affect adherence.
- Dose limitation is advised in significant renal or hepatic impairment and with potent CYP3A4 inhibitors.
Monitoring
Monitor symptomatic response and antimuscarinic side effects, periodically reviewing the need to continue therapy.
Counselling the patient
- Swallow the tablet whole and expect symptoms to improve gradually over a few weeks.
- Dry mouth and constipation are common; sips of water and dietary fibre may help.
- Report inability to pass urine or new eye pain and blurred vision.
Evidence & guidelines
NICE guidance on urinary incontinence supports antimuscarinics such as fesoterodine for overactive bladder where conservative treatment is inadequate.
Reference: NICE NG123; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.